| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,944 |
6,798 |
$3.27M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,695 |
3,909 |
$3.03M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,347 |
9,093 |
$2.97M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,776 |
1,520 |
$297K |
| 80053 |
Comprehensive metabolic panel |
11,448 |
9,856 |
$185K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
130 |
101 |
$142K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,495 |
2,005 |
$113K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
643 |
617 |
$106K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
752 |
634 |
$104K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
12,324 |
10,587 |
$100K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,785 |
1,512 |
$92K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,840 |
1,555 |
$84K |
| 70450 |
Computed tomography, head or brain; without contrast material |
176 |
161 |
$75K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
700 |
630 |
$71K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
607 |
490 |
$54K |
| 83605 |
|
3,592 |
2,986 |
$47K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
541 |
461 |
$46K |
| 36415 |
Collection of venous blood by venipuncture |
13,736 |
11,529 |
$43K |
| 71045 |
Radiologic examination, chest; single view |
1,028 |
887 |
$39K |
| 0240U |
|
282 |
251 |
$27K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,463 |
792 |
$23K |
| 83735 |
|
1,629 |
1,396 |
$19K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,179 |
813 |
$18K |
| 81001 |
|
4,318 |
3,759 |
$16K |
| 87430 |
|
1,010 |
946 |
$16K |
| 84484 |
|
1,402 |
1,134 |
$15K |
| 86140 |
|
1,636 |
1,411 |
$13K |
| J3490 |
Unclassified drugs |
1,663 |
1,088 |
$11K |
| 84145 |
|
192 |
162 |
$9K |
| 87040 |
|
1,086 |
735 |
$8K |
| 80305 |
|
1,217 |
1,090 |
$8K |
| 83690 |
|
1,016 |
887 |
$8K |
| 71046 |
Radiologic examination, chest; 2 views |
101 |
95 |
$8K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
35 |
33 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
240 |
218 |
$7K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
14 |
12 |
$7K |
| 82150 |
|
1,012 |
881 |
$7K |
| 87081 |
|
787 |
752 |
$6K |
| 80143 |
|
152 |
134 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
80 |
61 |
$4K |
| 85610 |
|
487 |
427 |
$4K |
| 85730 |
|
286 |
247 |
$4K |
| 80179 |
|
100 |
88 |
$3K |
| 81025 |
|
367 |
328 |
$3K |
| 83880 |
|
81 |
63 |
$2K |
| 87807 |
|
121 |
120 |
$2K |
| 80320 |
|
287 |
265 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
659 |
499 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
239 |
215 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
182 |
152 |
$901.03 |
| 87428 |
|
12 |
12 |
$894.25 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
93 |
72 |
$733.72 |
| 87186 |
|
62 |
62 |
$716.86 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
97 |
69 |
$678.35 |
| 82962 |
|
119 |
51 |
$618.40 |
| 96376 |
|
19 |
13 |
$617.38 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
84 |
68 |
$533.18 |
| 87077 |
|
42 |
40 |
$477.95 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
39 |
26 |
$105.45 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
174 |
104 |
$70.37 |
| 84703 |
|
17 |
14 |
$69.93 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
48 |
30 |
$52.56 |
| 85379 |
|
23 |
12 |
$42.08 |
| 81003 |
|
43 |
38 |
$30.84 |
| J7050 |
Infusion, normal saline solution, 250 cc |
312 |
202 |
$29.15 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
30 |
29 |
$20.16 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
47 |
29 |
$12.56 |
| 82947 |
|
22 |
13 |
$12.18 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
65 |
56 |
$0.50 |
| A9270 |
Non-covered item or service |
10,468 |
6,174 |
$0.00 |
| 80329 |
|
16 |
15 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
12 |
12 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
201 |
159 |
$0.00 |